CervoMed Inc. (CRVO) Stock Ticker
CRVO right now
Market factors today
Unlock the full CRVO picture
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
CRVO stock facts
| Ticker symbol | CRVO |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $23.5M |
| CEO | John J. Alam |
| Employees | 15 |
| Headquarters | Boston, MA, US |
| IPO date | 2008-05-23 |
| Website | www.cervomed.com |
What you can see for CRVO on Tickr
Live CRVO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CRVO report.
Rankings
FAQ
What is the ticker symbol for CervoMed Inc.?
The ticker symbol for CervoMed Inc. is CRVO, listed on the NASDAQ Capital Market.
What is CRVO?
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and…